← Back to Search

Monoclonal Antibodies

Dupilumab for Eosinophilic Esophagitis

Phase 4
Recruiting
Research Sponsored by Sanofi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
History (by participant report) of an average of at least 2 episodes of dysphagia (with intake of solids) per week in the 4 weeks prior to screening
Body weight ≥40 kg
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at weeks 24, 76 and 128
Awards & highlights

Study Summary

This trial will last for 2.5 years and will study the effects of a drug called dupilumab on esophageal function in adults with eosinophilic esophagitis.

Who is the study for?
Adults with a confirmed diagnosis of Eosinophilic Esophagitis (EoE) who experience at least two episodes of difficulty swallowing solid food per week and weigh over 40 kg can join. Those without proper biopsy confirmation or outside the weight criteria cannot participate.Check my eligibility
What is being tested?
The study is testing Dupilumab against a placebo to see its effects on esophageal function in EoE patients. Initially, participants are randomly assigned to receive either Dupilumab or placebo for six months, followed by everyone receiving Dupilumab for an additional two years.See study design
What are the potential side effects?
Dupilumab may cause side effects such as allergic reactions at the injection site, cold sores in your mouth or throat, and eye problems like redness, itching, or swelling.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had trouble swallowing solids at least twice a week in the last month.
Select...
I weigh at least 40 kg.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at weeks 24, 76 and 128
This trial's timeline: 3 weeks for screening, Varies for treatment, and at weeks 24, 76 and 128 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe (EndoFLIP)
Secondary outcome measures
Absolute change from baseline in esophageal distensibility plateau as measured by Functional Lumen Imaging Probe
Change from baseline in EoE-HSS Stage
Change from baseline in eosinophilic esophagitis (EoE-HSS) Grade
+8 more

Side effects data

From 2021 Phase 4 trial • 188 Patients • NCT04033367
9%
Conjunctivitis
7%
Headache
3%
Dermatitis Atopic
2%
Nasopharyngitis
1%
Accidental Overdose
1%
Drug Hypersensitivity
1%
Polyarthritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
DB Period: Placebo
DB Period: Dupilumab
OLE Period: Dupilumab/Dupilumab
OLE Period: Placebo/Dupilumab

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DupilumabExperimental Treatment1 Intervention
Subcutaneous injection (SC) as per protocol
Group II: PlaceboPlacebo Group1 Intervention
SC injection as per protocol
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab
2017
Completed Phase 4
~12230

Find a Location

Who is running the clinical trial?

SanofiLead Sponsor
2,171 Previous Clinical Trials
3,516,543 Total Patients Enrolled
5 Trials studying Eosinophilic Esophagitis
779 Patients Enrolled for Eosinophilic Esophagitis
Regeneron PharmaceuticalsIndustry Sponsor
628 Previous Clinical Trials
381,691 Total Patients Enrolled
7 Trials studying Eosinophilic Esophagitis
841 Patients Enrolled for Eosinophilic Esophagitis
Clinical Sciences & OperationsStudy DirectorSanofi
864 Previous Clinical Trials
2,019,993 Total Patients Enrolled
~43 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top